Results of the Phase III DASISION trial and the future of CML treatment
Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Drug–drug interactions & the potential impact on toxicity levels in patients with B-cell malignancy
What is the rationale for novel combination therapies?
Niels van de Donk
Graft versus host disease: how to treat it?